Get the Stockscreener App
7.33
2.81%
+0.20
Fulcrum Therapeutics Inc stock is currently priced at $7.33, with a 24-hour trading volume of 359.31K.
It has seen a +2.81% increased in the last 24 hours and a -21.27% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.12 pivot point. If it approaches the $7.38 resistance level, significant changes may occur.
Previous Close:
$7.13
Open:
$7.16
24h Volume:
359.31K
Market Cap:
$455.59M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.0722
EPS:
-1.8
Net Cash Flow:
$-91.47M
1W Performance:
+0.69%
1M Performance:
-21.27%
6M Performance:
+95.47%
1Y Performance:
+169.49%
1D Range:
$7.14
$7.51
52W Range:
$2.625
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 Landsdowne Street, Cambridge, MA
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
GlobeNewswire Inc.
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Benzinga
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
GlobeNewswire Inc.
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Benzinga
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Fulcrum Therapeutics Inc (FULC) Revenue 2024
FULC reported a revenue (TTM) of $2.81 million for the quarter ending December 31, 2023, a -55.77% decline year-over-year.
Fulcrum Therapeutics Inc (FULC) Net Income 2024
FULC net income (TTM) was -$97.33 million for the quarter ending December 31, 2023, a +11.41% increase year-over-year.
Fulcrum Therapeutics Inc (FULC) Cash Flow 2024
FULC recorded a free cash flow (TTM) of -$91.47 million for the quarter ending December 31, 2023, a +7.62% increase year-over-year.
Fulcrum Therapeutics Inc (FULC) Earnings per Share 2024
FULC earnings per share (TTM) was -$1.58 for the quarter ending December 31, 2023, a +36.29% growth year-over-year.
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
3.18%
Cap:
|
Volume (24h):